NEW YORK (GenomeWeb News) — Shares in Cepheid were up 6 percent to a new 52-week high of $12.47 in mid-afternoon trading today after the company this morning said the US Food and Drug Administration cleared one of its tests.
 
As GenomeWeb Daily News reported this morning, the company’s PCR-based Xpert MRSA test is designed to detect drug-resistant Staphylococcus aureus infections.   
  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.